{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T12:08:00Z","timestamp":1771502880321,"version":"3.50.1"},"reference-count":22,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2023,6,4]],"date-time":"2023-06-04T00:00:00Z","timestamp":1685836800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Treatment for endometrial cancer is rapidly evolving with the increased use and integration of somatic tumor RNA sequencing in clinical practice. There is a paucity of data regarding PARP inhibition in endometrial cancer given that mutations in homologous recombination genes are rare, and currently no FDA approval exists. A 50-year-old gravida 1 para 1 woman with a diagnosis of stage IVB poorly differentiated endometrioid endometrial adenocarcinoma presented to our comprehensive cancer center. Following surgical staging, she was placed on adjuvant chemotherapy with carboplatin\/paclitaxel which was held multiple times due to poor performance status and complications. CT scan of the abdomen and pelvis following cycles 3 of adjuvant chemotherapy showed recurrent progressive disease. She received one cycle of liposomal doxorubicin but discontinued it due to severe cutaneous toxicity. Based on the BRIP1 mutation identified, the patient was placed on compassionate use of Olaparib in January 2020. Imaging during this surveillance period showed a significant decrease in hepatic, peritoneal, and extraperitoneal metastases, and eventually the patient had a clinical complete response in a year. The most recent CT A\/P in December 2022 showed no sites of active recurrent or metastatic disease in the abdomen or pelvis. We present a unique case of a patient with recurrent stage IVB poorly differentiated endometrioid endometrial adenocarcinoma with multiple somatic gene mutations including BRIP1, who had a pathologic complete response following compassionate use of Olaparib for 3 years. To our knowledge, this is the first reported case of high grade endometrioid endometrial cancer that has shown a pathologic complete response to a PARP inhibitor.<\/jats:p>","DOI":"10.3390\/jcm12113839","type":"journal-article","created":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T02:18:29Z","timestamp":1685931509000},"page":"3839","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Complete Pathologic Response to PARP Inhibitor Olaparib in a Patient with Stage IVB Recurrent Endometrioid Endometrial Adenocarcinoma"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4856-4051","authenticated-orcid":false,"given":"Rosemary Noel","family":"Senguttuvan","sequence":"first","affiliation":[{"name":"Department of Surgery, City of Hope Comprehensive Cancer Center (COH), Duarte, CA 91010, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Pathology, City of Hope Comprehensive Cancer Center (COH), Duarte, CA 91010, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mustafa","family":"Raoof","sequence":"additional","affiliation":[{"name":"Department of Surgery, City of Hope Comprehensive Cancer Center (COH), Duarte, CA 91010, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1855-1989","authenticated-orcid":false,"given":"Thanh H.","family":"Dellinger","sequence":"additional","affiliation":[{"name":"Department of Surgery, City of Hope Comprehensive Cancer Center (COH), Duarte, CA 91010, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward Wenge","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, City of Hope Comprehensive Cancer Center (COH), Duarte, CA 91010, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,6,4]]},"reference":[{"key":"ref_1","unstructured":"(2023, April 17). Cancer Stat Facts: Uterine Cancer, Available online: https:\/\/seer.cancer.gov\/statfacts\/html\/corp.html."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.ygyno.2014.02.011","article-title":"Tumor size, depth of invasion, and histologic grade as prognostic factors of lymph node involvement in endometrial cancer: A SEER analysis","volume":"133","author":"Vargas","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/S1470-2045(19)30395-X","article-title":"Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): Patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial","volume":"20","author":"Powell","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Levine","year":"2013","journal-title":"Nature"},{"key":"ref_5","unstructured":"(2023, April 17). Uterine Neoplasms. Available online: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/uterine.pdf."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1136\/ijgc-2022-004039","article-title":"Refining adjuvant treatment in endometrial cancer based on molecular features: The RAINBO clinical trial program","volume":"33","author":"Consortium","year":"2023","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer","volume":"381","author":"Pothuri","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3952","DOI":"10.1200\/JCO.22.01003","article-title":"A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients with Newly Diagnosed Ovarian Cancer (ATHENA\u2013MONO\/GOG-3020\/ENGOT-ov45)","volume":"40","author":"Monk","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S1470-2045(21)00073-5","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): A final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"22","author":"Poveda","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/S1470-2045(22)00122-X","article-title":"Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): An international, open-label, randomised, phase 3 trial","volume":"23","author":"Kristeleit","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00286","article-title":"Prevalence of Homologous Recombination-Related Gene Mutations Across Multiple Cancer Types","volume":"2018","author":"Heeke","year":"2018","journal-title":"JCO Precis Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"TPS6109","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS6109","article-title":"Multicentre randomized phase II trial of olaparib as maintenance therapy in platinum-sensitive advanced endometrial carcinoma: The GINECO-UTOLA study","volume":"38","author":"Joly","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"6123","DOI":"10.2147\/CMAR.S221001","article-title":"PARP Inhibitors in Endometrial Cancer: Current Status and Perspectives","volume":"12","author":"Musacchio","year":"2020","journal-title":"Cancer Manag. Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"726","DOI":"10.18632\/oncotarget.27945","article-title":"Analytic validation and clinical utilization of the comprehensive genomic profiling test, GEM ExTra(\u00ae)","volume":"12","author":"White","year":"2021","journal-title":"Oncotarget"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/gim.2013.92","article-title":"ACMG clinical laboratory standards for next-generation sequencing","volume":"15","author":"Rehm","year":"2013","journal-title":"Genet. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1200\/PO.19.00368","article-title":"Olaparib Monotherapy for BRIP1-Mutated High-Grade Serous Endometrial Cancer","volume":"4","author":"Nakamura","year":"2020","journal-title":"JCO Precis. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1126\/science.1088753","article-title":"The BRCT domain is a phospho-protein binding domain","volume":"302","author":"Yu","year":"2003","journal-title":"Science"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"289","DOI":"10.2741\/e767","article-title":"BRIP1, a potential candidate gene in development of non-BRCA1\/2 breast cancer","volume":"8","author":"Ouhtit","year":"2016","journal-title":"Front. Biosci. Elite Ed."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"5893","DOI":"10.1038\/s41388-021-01984-2","article-title":"POLE, POLD1, and NTHL1: The last but not the least hereditary cancer-predisposing genes","volume":"40","author":"Magrin","year":"2021","journal-title":"Oncogene"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Abe, A., Imoto, I., Ueki, A., Nomura, H., and Kanao, H. (2022). Moderate-Risk Genes for Hereditary Ovarian Cancers Involved in the Homologous Recombination Repair Pathway. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms231911790"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/11\/3839\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:47:55Z","timestamp":1760125675000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/11\/3839"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,4]]},"references-count":22,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,6]]}},"alternative-id":["jcm12113839"],"URL":"https:\/\/doi.org\/10.3390\/jcm12113839","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,4]]}}}